SBS

Zealand Pharma Announces Financial Results for the First Quarter of 2024

Retrieved on: 
torsdag, maj 16, 2024
DREAM, Partnership, Credit, Patient, European Investment Bank, F2, CGM, Short bowel syndrome, Complement component 3, NDA, US FDA, Obesity, EASL, Clinical trial, Congress, Overweight, FDA, S&M, DKK, Boehringer Ingelheim, Danske Bank, PDUFA, Cirrhosis, EUR, SBS, F1, Weight loss, Part, G&A, EIB, BofA Securities, Pharmaceutical industry

Cash position includes cash, cash equivalents and marketable securities, as well as Tranche A of EIB loan disbursed in Q1 2024.

Key Points: 
  • Cash position includes cash, cash equivalents and marketable securities, as well as Tranche A of EIB loan disbursed in Q1 2024.
  • Survodutide, a glucagon/GLP-1 receptor dual agonist: Boehringer Ingelheim announced positive results from Phase 2 trial in MASH.
  • These results will be presented at the European Association for the Study of the Liver (EASL) congress in Milan, Italy on June 7, 2024.
  • Zealand expects to initiate the first-in-human clinical trial of ZP9830 in the second half of 2024.

Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Retrieved on: 
tisdag, maj 21, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SBS, DDW, White, Short bowel syndrome, Diagnosis, Food, NDA, Clinical trial, FDA, FRCS, Medication, Overalls, Safety, Ironwood Pharmaceuticals, Marketing, FACS, CIC, Transplant, STARS, Cedars-Sinai Medical Center, HCP, IBS, MBBS, Principal, PS, Pharmaceutical industry

Apraglutide is the first and only investigational once-weekly GLP-2 analog that has successfully demonstrated positive results in a Phase III placebo-controlled study.

Key Points: 
  • Apraglutide is the first and only investigational once-weekly GLP-2 analog that has successfully demonstrated positive results in a Phase III placebo-controlled study.
  • Treatment effect with relative PS volume reduction was observed from week 8 onward (-8% vs -1.6% placebo, p=0.002).
  • Three additional colon-in-continuity patients achieved enteral autonomy by week 48: 7/56 [12.5%] apraglutide vs 2/27 placebo [7.4%], p=0.387.
  • Apraglutide was well-tolerated, with no new safety signals identified and the safety profile was consistent with previous apraglutide studies.

EnerSys Secures Energy Storage Product of the Year Award

Retrieved on: 
fredag, maj 17, 2024
EV, Electric Vehicles, Utilities, Sustainability, Batteries, Energy, Technology, Aftermarket, Automotive, Commercial Building & Real Estate, Construction & Property, Environment, Engineering, Manufacturing, Energy storage, ENS, Carbon, Industrial, SBS, Total cost, Total cost of ownership, Renewable energy

EnerSys (NYSE: ENS), the global leader in stored energy solutions for industrial applications, has secured the 2024 Energy Storage Product of the Year Award at the Electrical Review and Data Centre Review Excellence Awards.

Key Points: 
  • EnerSys (NYSE: ENS), the global leader in stored energy solutions for industrial applications, has secured the 2024 Energy Storage Product of the Year Award at the Electrical Review and Data Centre Review Excellence Awards.
  • EnerSys was also shortlisted for the Energy Storage / UPS Project of the Year and Data Center Power Project of the Year Awards.
  • This recognition is a testament to the Company’s commitment to excellence, innovation, and sustainability in industrial and utility energy storage and power management.
  • For more information about EnerSys' full line of products, systems, and support, visit the Industries section of our website at www.enersys.com .

Ironwood Pharmaceuticals Reports First Quarter 2024 Results

Retrieved on: 
torsdag, maj 9, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, PS, Phase, Capsule, The Lancet, Gastrointestinal disease, Safety, AbbVie, Food, Interstitial cystitis, SBS, Depreciation, Interest, Trial of the century, Endometriosis, Research, Hepatology, IQVIA, Disease, Autoimmune disease, Patient, Liver, Acquisition, Short bowel syndrome, Constipation, DDW, STARS, Primary biliary cholangitis, Bank statement, Adjustment, Standard of care, Clinical trial, PBC, GAAP, Food and Drug Administration, Income tax, Ageing, Pharmaceutical industry

LINZESS commercial margin, excluding the gross-to-net change in estimate, was 71% in the first quarter of 2024, compared to 73% in the first quarter of 2023.

Key Points: 
  • LINZESS commercial margin, excluding the gross-to-net change in estimate, was 71% in the first quarter of 2024, compared to 73% in the first quarter of 2023.
  • Total revenue in the first quarter of 2024 was $74.9 million, compared to $104.1 million in the first quarter of 2023.
  • Operating expenses in the first quarter of 2024 were $63.9 million, compared to $44.0 million in the first quarter of 2023.
  • Ironwood generated $45.0 million in cash from operations in the first quarter of 2024, compared to $80.2 million in cash from operations in the first quarter of 2023.

KBRA Releases Monthly CMBS Trend Watch

Retrieved on: 
fredag, maj 3, 2024
Professional Services, Finance, CMBS, KBRA, CRE, SBS, Agency, Research, Freddie Mac, Publication

KBRA releases the April 2024 issue of CMBS Trend Watch.

Key Points: 
  • KBRA releases the April 2024 issue of CMBS Trend Watch.
  • U.S. private label CMBS issuance slowed to $6.4 billion in April from $9 billion in March amid widening spreads.
  • There were 11 deals including nine single-borrower (SB) and two conduit deals that priced in April, with year-over-year volume up 213%.
  • In April, KBRA published pre-sales for seven deals ($5.9 billion) including four SB ($3.2 billion), two conduits ($1.8 billion), and one Agency ($866 million).

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024

Retrieved on: 
onsdag, maj 1, 2024
Biotechnology, Health, Science, Other Science, Pharmaceutical, PS, FDA, Irritable bowel syndrome, Safety, Functional constipation, Gastrointestinal disease, Diagnosis, NDA, Food, SBS, Ironwood Pharmaceuticals, Short bowel syndrome, Effect, Research, IBS-C, Ironwood, Constipation, DDW, STARS, FC, Drug development, Medication, IBS, Pharmaceutical industry

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which patients are dependent on parenteral support (PS), during the 2024 Digestive Disease Week® (DDW) meeting.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which patients are dependent on parenteral support (PS), during the 2024 Digestive Disease Week® (DDW) meeting.
  • Apraglutide data from the STARS Phase III trial, which evaluated the safety and efficacy of once-weekly apraglutide in reducing PS dependency in adult patients with SBS-IF, will be presented at DDW 2024 as a late-breaker oral presentation.
  • Ironwood announced topline data from the STARS Phase III trial in February 2024.
  • The late-breaker presentation includes new apraglutide data from the STARS Phase III trial.

The Marygold Companies’ Subsidiary, Marygold & Co. (UK), Acquires UK-Based Financial Advisory Firm

Retrieved on: 
onsdag, maj 1, 2024
Professional Services, Finance, Asset Management, Fintech, Consulting, Banking, Personal Finance, Acquisition, SBS, Marigold, Gerber, Financial services

The Marygold Companies, Inc. (“TMC,” or the “Company”) (NYSE American: MGLD), a diversified global holding firm, today announced that its wholly owned subsidiary, Marygold & Co. (UK) Limited, has completed the acquisition of Step-By-Step Financial Planners Limited (“SBS”), an investment advisory firm based in Rugeley, Staffordshire, England.

Key Points: 
  • The Marygold Companies, Inc. (“TMC,” or the “Company”) (NYSE American: MGLD), a diversified global holding firm, today announced that its wholly owned subsidiary, Marygold & Co. (UK) Limited, has completed the acquisition of Step-By-Step Financial Planners Limited (“SBS”), an investment advisory firm based in Rugeley, Staffordshire, England.
  • SBS has approximately US$33.7 million (£27 million) in assets under management and provides a full range of financial advisory services to individuals and companies across a diverse product range, including wealth management.
  • Kevin Pratt, the founder of SBS, and his team will continue with the company and provide ongoing advice and continuity to the clients.
  • “It represents the second acquisition completed by Marygold & Co. (UK), following the purchase in 2022 of UK-based financial advisory firm Tiger Financial & Asset Management Limited.

AG&P LNG Awarded 20-year Contract by PLN EPI, Indonesia for Co-development, Ownership and Operations of LNG Import Terminals in Sulawesi-Maluku Power Cluster

Retrieved on: 
tisdag, mars 26, 2024
Energi, Carbon, SBS, Natural gas, MTPA, JV, AG, Partnership, Acquisition, LNG carrier, PLN, Consortium, Plant, Investment, FSRU, PT PLN

SINGAPORE, March 26, 2024 /PRNewswire/ -- Leading LNG terminals and downstream infrastructure company, AG&P LNG, majority-owned by Nebula Energy, announced today that its subsidiary PT AGP Indonesia Utama (AG&P Indonesia), along with consortium members Suasa Benua Sukses (SBS) and KPMOG, collectively referred to as the Consortium, has won a large-scale 20-year contract for LNG infrastructure from PLN EPI in Indonesia. The tender was awarded to AG&P LNG for the co-development, ownership and operations of LNG import terminal infrastructure and downstream logistics in seven locations within the Sulawesi-Maluku cluster in Indonesia. The customer and co-shareholder in this facility will be PT PLN Energi Primer (PLN EPI), a wholly owned subsidiary of PT PLN (Persero) Indonesia.

Key Points: 
  • PT PLN Energi Primer (PLN EPI), a wholly owned subsidiary of PT PLN (Persero) Indonesia will be the customer and co-shareholder in the facility.
  • The tender was awarded to AG&P LNG for the co-development, ownership and operations of LNG import terminal infrastructure and downstream logistics in seven locations within the Sulawesi-Maluku cluster in Indonesia.
  • The customer and co-shareholder in this facility will be PT PLN Energi Primer (PLN EPI), a wholly owned subsidiary of PT PLN (Persero) Indonesia.
  • Among its LNG terminal project portfolio, AG&P LNG is the operator of the first LNG import and regasification terminal in the Philippines, the Philippines LNG (PHLNG) Import Terminal located in Batangas Bay.

AG&P LNG Awarded 20-year Contract by PLN EPI, Indonesia for Co-development, Ownership and Operations of LNG Import Terminals in Sulawesi-Maluku Power Cluster

Retrieved on: 
tisdag, mars 26, 2024
Energi, Carbon, SBS, Natural gas, MTPA, JV, AG, Partnership, Acquisition, LNG carrier, PLN, Consortium, Plant, Investment, FSRU, PT PLN

SINGAPORE, March 26, 2024 /PRNewswire/ -- Leading LNG terminals and downstream infrastructure company, AG&P LNG, majority-owned by Nebula Energy, announced today that its subsidiary PT AGP Indonesia Utama (AG&P Indonesia), along with consortium members Suasa Benua Sukses (SBS) and KPMOG, collectively referred to as the Consortium, has won a large-scale 20-year contract for LNG infrastructure from PLN EPI in Indonesia. The tender was awarded to AG&P LNG for the co-development, ownership and operations of LNG import terminal infrastructure and downstream logistics in seven locations within the Sulawesi-Maluku cluster in Indonesia. The customer and co-shareholder in this facility will be PT PLN Energi Primer (PLN EPI), a wholly owned subsidiary of PT PLN (Persero) Indonesia.

Key Points: 
  • PT PLN Energi Primer (PLN EPI), a wholly owned subsidiary of PT PLN (Persero) Indonesia will be the customer and co-shareholder in the facility.
  • The tender was awarded to AG&P LNG for the co-development, ownership and operations of LNG import terminal infrastructure and downstream logistics in seven locations within the Sulawesi-Maluku cluster in Indonesia.
  • The customer and co-shareholder in this facility will be PT PLN Energi Primer (PLN EPI), a wholly owned subsidiary of PT PLN (Persero) Indonesia.
  • Among its LNG terminal project portfolio, AG&P LNG is the operator of the first LNG import and regasification terminal in the Philippines, the Philippines LNG (PHLNG) Import Terminal located in Batangas Bay.

SBS TO RECEIVE MULTIMILLION DOLLAR SETTLEMENT FROM VOZ MEDIA

Retrieved on: 
måndag, mars 18, 2024
OTC Markets Group, SBS, Acquisition, VOZ

MIAMI, March 18, 2024 /PRNewswire/ -- Spanish Broadcasting System, Inc. ("SBS" or "the Company") (OTC Pink: SBSAA) announced today that it had reached a multimillion dollar out-of-court settlement with VOZ Media regarding VOZ's default of its $64 Million acquisition of the SBS Mega TV division.

Key Points: 
  • MIAMI, March 18, 2024 /PRNewswire/ -- Spanish Broadcasting System, Inc. ("SBS" or "the Company") (OTC Pink: SBSAA) announced today that it had reached a multimillion dollar out-of-court settlement with VOZ Media regarding VOZ's default of its $64 Million acquisition of the SBS Mega TV division.
  • The amount of the settlement was not disclosed.
  • The settlement is in addition to a $3.8 Million deposit SBS had previously retained after VOZ failed to close on the TV transaction in 2023.
  • An SBS spokesperson stated that the Company was pleased with the out-of-court settlement and the outcome of the litigation.